img
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP 1 Inhibitor Therapy in Colon Cancer     
Yazarlar
Prof. Dr. Özkan ÖZDEN Prof. Dr. Özkan ÖZDEN
Kafkas Üniversitesi, Türkiye
Faraz Bishehsari
Türkiye
Jessica Bauer
Türkiye
Seonghoon Park
Türkiye
Arundhati Jana
Türkiye
Seung Hyun Baik
Türkiye
Judith Sporn
Türkiye
Jonas J Staudacher
Türkiye
Cemal Yazici
Türkiye
Nancy Krett
Türkiye
Barbara Jung
Türkiye
Özet
BRCA1-associated RING domain protein 1 (BARD1) stabilizes BRCA1 protein by forming a heterodimeric RING-RING complex, and impacts function of BRCA1, including homologous recombination (HR) repair. Although colon cancer cells usually express wild type BRCA1, presence of an oncogenic BARD1 splice variant (SV) in select cancers may render BRCA1 dysfunctional and allow cells to become sensitive to HR targeting therapies. We previously reported association of loss of full-length (FL) BARD1 with poor prognosis in colon cancer as well as expression of various BARD1 SVs with unknown function. Here we show that loss of BARD1 function through the expression of a BARD1 SV, BARD1β, results in a more malignant phenotype with decreased RAD51 foci formation, reduced BRCA1 E3 ubiquitin ligase activity, and decreased nuclear BRCA1 protein localization. BARD1β sensitizes colon cancer cells to poly ADP ribose polymerase 1 (PARP-1) inhibition even in a FL BRCA1 background. These results suggest that expression of BARD1β may serve as a future biomarker to assess suitability of colon cancers for HR targeting with PARP-1 inhibitors in treatment of advanced colon cancer.
Anahtar Kelimeler
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı SCIENTIFIC REPORTS
Dergi ISSN 2045-2322
Dergi Tarandığı Indeksler SCI
Makale Dili İngilizce
Basım Tarihi 05-2016
Cilt No 6
Sayfalar 26273 / 0
Doi Numarası 10.1038/srep26273
Makale Linki http://www.nature.com/articles/srep26273